Joint Initiative in Vaccine Economics, Phase 4 (JIVE 4)

Faculty Contact: Lisa A. Prosser, PhD

During the last ten years, the number of vaccines in the childhood vaccination schedule has doubled and the number of adolescent and adult vaccines recommended by the Advisory Committee for Immunization Practices (ACIP) has increased substantially, increasing the need for information on vaccine economics. Economic evaluation has long been a standard part of the ACIP process considered along with evidence on disease burden, vaccine effectiveness, potential risks, and other clinical and policy considerations.

The overall goal of this research study is to inform vaccine policy recommendations under consideration by ACIP, CDC, and other state and local decision makers using economic evaluation, decision analysis, and related research methods. The findings from this study will provide key information to inform vaccine policy decisions.

Research Topic & Methods:
The Joint Initiative in Vaccine Economics, Phase 4 (JIVE 4) consists of three research projects. The initial study will develop an epidemic model of infectious disease spread to estimate the change in health and economic effects of vaccination coverage that can be used to evaluate interventions aimed at improving coverage rates. The second study will characterize the conditions under which it would be favorable to pursue the development of a new pertussis vaccine by identifying recommended vaccine features and characterizing vaccine development costs. The third study will use conjoint analysis to identify barriers and facilitators to adolescent and adult vaccination that can be used to identify alternative settings for vaccination, also designed to improve coverage rates.

Specific Aims:

  1. To measure the economic value of changes in vaccination coverage on health outcomes, costs, and cost-effectiveness by:
    1. Developing a theoretical model of the economic value of vaccination in the US
    2. Evaluating how projected outcomes vary based on changes to model parameters
    3. Developing and testing an empirical model of the changes in vaccination coverage using a dynamic modeling approach.
  2. To conduct a needs assessment and feasibility study of a new pertussis vaccine.
    1. Identify recommended features for a new pertussis vaccine via key informant interviews with pertussis and vaccination experts
    2. Characterize costs associated with R&D, licensure, and other costs of bringing a new vaccine to market, using established modeling methods. 
  3. To measure barriers and facilitators to adolescent and adult vaccination using conjoint analysis.

Funded by the Centers for Disease Control and Prevention

For more information, please contact:
Lisa A. Prosser, PhD
University of Michigan Child Health Evaluation and Research (CHEAR) Unit
Division of General Pediatrics
University of Michigan
300 North Ingalls, Rm 6A14
Ann Arbor, MI 48109-5456
Telephone: (734) 232-1077 Fax: (734) 936-0941
Email: lisapros[at]med.umich[dot]edu